Metformin

Basic Information

CAS ID: 657-24-9
Molecular Formula: C4H11N5
Molecular Weight: 129.2 g/mol
Monoisotopic Mass: 129.1014 g/mol
Class: Small Molecule
Natural Product: No
Other Names: GLUMETZA | DIAGEMET XL | METABET SR | SUKKARTO SR | GLUCOPHAGE SR | MILFORM | GLUCIENT SR | METSOL | LEDERMETIN | GLUCAMET 500 | FORTAMET | RIOMET | ORABET | GLYFORMIN | GLUCOPHAGE XR | GLUCOPHAGE | BOLAMYN SR | LA-6023 | GLUCAMET 850 | METFORMIN | METFORMIN HYDROCHLORIDE | Janumet
Analysis: Drug repositioning mechanism analysis

N NH NH NH NH2

Compound Structure and Identifier

InChI: InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8) See All
InChI Key: XZWYZXLIPXDOLR-UHFFFAOYSA-N
Smiles: CN(C)C(=N)NC(=N)N See All
Molfile: Download

Related Target

Target ID Name Interaction
T0382 5'-AMP-activated protein kinase subunit beta-1 activator
T1021 AMP-activated protein kinase agonist

Related Fibrosis Property

Reference Record 1

PubMed ID 25503637 Target ID T0382
Uniprot ID 5'-AMP-activated protein kinase subunit beta-1 Name 5'-AMP-activated protein kinase subunit beta-1
Model rat Fibrosis Disease Renal fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism

Reference Record 2

PubMed ID 25428127 Target ID T0382
Uniprot ID 5'-AMP-activated protein kinase subunit beta-1 Name 5'-AMP-activated protein kinase subunit beta-1
Model vitro Fibrosis Disease Renal fibrosis
Process I
Process II EMT
Process III
Mechanism

Reference Record 3

PubMed ID 23825068 Target ID
Uniprot ID Name
Model rat Fibrosis Disease Renal fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism Targeting AMPK

Reference Record 4

PubMed ID 23122726 Target ID
Uniprot ID Name
Model rat Fibrosis Disease Cardiac fibrosis
Process I
Process II
Process III prevenet collagen deposition
Mechanism

Reference Record 5

PubMed ID 21567395 Target ID T1021
Uniprot ID AMP-activated protein kinase Name AMP-activated protein kinase
Model vitro Fibrosis Disease Liver fibrosis
Process I
Process II myofibroblasts differentiation
Process III prevenet collagen deposition
Mechanism

Trial Record 1

ClinicalTrial ID NCT02306070 Disease Liver fibrosis
Phase Phase 2 Status Withdrawn
First Received December 3, 2014 Last Verified April 17, 2018
Sponsor Ottawa Hospital Research Institute

Trial Record 2

ClinicalTrial ID NCT02470546 Disease Liver fibrosis
Phase Phase 4 Status Unknown
First Received June 12, 2015 Last Verified June 12, 2015
Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Trial Record 3

ClinicalTrial ID NCT02234440 Disease Liver fibrosis
Phase Not Applicable Status Completed
First Received September 9, 2014 Last Verified February 8, 2018
Sponsor Institute of Liver and Biliary Sciences, India

Trial Record 4

ClinicalTrial ID NCT02319200 Disease Liver fibrosis
Phase Phase 3 Status Terminated
First Received December 18, 2014 Last Verified January 11, 2017
Sponsor Assistance Publique - Hôpitaux de Paris

Related Link

PubChem: 4091
ChEMBL: CHEMBL1431